WO2004089285A3 - Phosphodiesterase 2a and methods of use - Google Patents

Phosphodiesterase 2a and methods of use Download PDF

Info

Publication number
WO2004089285A3
WO2004089285A3 PCT/US2004/010060 US2004010060W WO2004089285A3 WO 2004089285 A3 WO2004089285 A3 WO 2004089285A3 US 2004010060 W US2004010060 W US 2004010060W WO 2004089285 A3 WO2004089285 A3 WO 2004089285A3
Authority
WO
WIPO (PCT)
Prior art keywords
pde2a
polypeptides
methods
phosphodiesterase
relates
Prior art date
Application number
PCT/US2004/010060
Other languages
French (fr)
Other versions
WO2004089285A2 (en
Inventor
Daguang Wang
Bozena Bugaj-Gaweda
Original Assignee
Memory Pharm Corp
Daguang Wang
Bozena Bugaj-Gaweda
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Memory Pharm Corp, Daguang Wang, Bozena Bugaj-Gaweda filed Critical Memory Pharm Corp
Priority to EP04749633A priority Critical patent/EP1610755A2/en
Priority to US10/545,501 priority patent/US20060168668A1/en
Priority to CA002520866A priority patent/CA2520866A1/en
Publication of WO2004089285A2 publication Critical patent/WO2004089285A2/en
Publication of WO2004089285A3 publication Critical patent/WO2004089285A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/44—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving esterase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/24—Immunology or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders

Abstract

The invention relates to phosphodiesterase PDE2A isoforms, as well as nucleic acids encoding such polypeptides. The invention further relates to methods for utilizing such polypeptides in diagnostic assays and in methods of screenin potential modulators, especially inhibitors, of the novel PDE2A disclosed herein. The polypeptides of the invention are involved in many physiological processes including, e.g. the formation of memory, cognitive function, and other disease and conditions which involve or are mediated by PDE2A and its signaling pathways.
PCT/US2004/010060 2003-04-04 2004-04-01 Phosphodiesterase 2a and methods of use WO2004089285A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP04749633A EP1610755A2 (en) 2003-04-04 2004-04-01 Phosphodiesterase 2a and methods of use
US10/545,501 US20060168668A1 (en) 2003-04-04 2004-04-01 Phosphodiesterase 2a and methods of use
CA002520866A CA2520866A1 (en) 2003-04-04 2004-04-01 Phosphodiesterase 2a and methods of use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45997703P 2003-04-04 2003-04-04
US60/459,977 2003-04-04

Publications (2)

Publication Number Publication Date
WO2004089285A2 WO2004089285A2 (en) 2004-10-21
WO2004089285A3 true WO2004089285A3 (en) 2006-02-16

Family

ID=33159716

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/010060 WO2004089285A2 (en) 2003-04-04 2004-04-01 Phosphodiesterase 2a and methods of use

Country Status (4)

Country Link
US (1) US20060168668A1 (en)
EP (1) EP1610755A2 (en)
CA (1) CA2520866A1 (en)
WO (1) WO2004089285A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102006048693A1 (en) * 2006-10-14 2008-04-17 Bayer Healthcare Ag Inhibition of PDE2A
US20090110638A1 (en) * 2007-10-24 2009-04-30 California Institute Of Technology Methods using the grueneberg ganglion chemosensory system

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [online] 30 May 2001 (2001-05-30), MAW ET AL: "Treatment of femal sexual dysfunction.", XP002993725, accession no. ncbi Database accession no. (AX138999) *

Also Published As

Publication number Publication date
WO2004089285A2 (en) 2004-10-21
EP1610755A2 (en) 2006-01-04
US20060168668A1 (en) 2006-07-27
CA2520866A1 (en) 2004-10-21

Similar Documents

Publication Publication Date Title
DE602005020209D1 (en) System for the evaluation of cardiac disorders
WO2007092640A3 (en) Antibodies that bind par-2
WO2006020269A3 (en) Biomarkers of neurodegenerative disease
BRPI0513029A (en) method for producing a carbamylated erythropoietin protein, carbamylated erythropoietin protein, compound, pharmaceutical composition, methods of treating a chronic, sub-chronic and acute disease or condition and treating a disease of the central nervous system or peripheral nervous system, and , use of a compound
WO2007051164A8 (en) Toll like receptor 3 modulators, methods and uses
WO2008136848A3 (en) Novel anti-notch3 antibodies and their use in the detection and diagnosis of disease
WO2004067570A3 (en) Prostate cancer diagnosis and treatment
WO2005019264A3 (en) Human lxr alpha variants
WO2007059341A3 (en) Pyrazolothiazole protein kinase modulators
WO2006072954A3 (en) Novel il-6 polynucleotides encoding variant il-6 polypeptides and methods using same
WO2005000875A3 (en) Compositions and methods comprising a ligand of chemerin receptor
WO2005054871A3 (en) Analysis of mass spectral data in the quiet zones
WO2004015060A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2005017187A3 (en) Methods for screening and identifying compounds
WO2004042083A3 (en) Nucleic acid ligands and uses therefor
WO2005094898A3 (en) Chemically modified protein compositions and methods
WO2004089285A3 (en) Phosphodiesterase 2a and methods of use
MXPA03007928A (en) Improved process for producing emulsified salad dressings background of the invention.
WO2006043060A3 (en) Mam domain containing protein
WO2002099116A8 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004094641A3 (en) A novel method of modulating bone-realted activity
WO2003074007A3 (en) Modulators of leukocyte activation, compositions, and methods of use
WO2001074851A3 (en) Novel proteins and nucleic acids encoding same
WO2002083841A3 (en) Therapeutic polypeptides, nucleic acids encoding same, and methods of use
WO2004009786A3 (en) Modulators of leukocyte activation, bic compositions and methods of use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2006168668

Country of ref document: US

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 10545501

Country of ref document: US

WWE Wipo information: entry into national phase

Ref document number: 2004749633

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2520866

Country of ref document: CA

WWP Wipo information: published in national office

Ref document number: 2004749633

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 10545501

Country of ref document: US

WWW Wipo information: withdrawn in national office

Ref document number: 2004749633

Country of ref document: EP